Tetrabenazine — Membership Pricing

Other medications in Neurology

• Topiramate
• Valproic Acid
• Carbamazepine
• Deutetrabenazine
• Lamotrigine
• Levetiracetam
• Phenytoin
• Selegiline Oral

About Tetrabenazine

Tetrabenazine is a specialized medication used to manage involuntary movements associated with certain neurological conditions. For individuals grappling with the challenges of conditions like Huntington's disease or tardive dyskinesia, tetrabenazine offers a ray of hope. At TheDrugClub, we understand the importance of accessing vital medications, and we're committed to helping our members find potential savings on their prescriptions.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tetrabenazine is approved for (FDA label)

Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington’s disease. Tetrabenazine tablets are a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

Source: Read the full FDA label on DailyMed. Label effective date: July 5, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Tetrabenazine (FDA label)

WARNING: DEPRESSION AND SUICIDALITY Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of tetrabenazine tablets must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. Tetrabenazine tablets are contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression [see Contraindications (4), Warnings and Precautions (5.1)] . WARNING: DEPRESSION AND SUICIDALITY See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 5042f30c-c922-4835-bf6d-40905f2dc76c. SPL document ID: b4b833f2-4424-46a8-b5df-ad62c36c7d75. Label effective date: July 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tetrabenazine (FDA label)

Tetrabenazine tablets, USP are available in the following strengths and packages: The 12.5 mg Tetrabenazine tablets, USP are light yellow to yellow, round shaped, flat, beveled edge tablets, debossed with “T” 12.5 on one side and plain on other side. The 25 mg Tetrabenazine tablets, USP are light yellow to yellow, round shaped, flat, beveled edge tablets, debossed with “T 25” on one side and functional scoreline on other side. Tablets: 12.5 mg non-scored and 25 mg with functional score

Source: FDA prescribing information (DailyMed). Set ID: 5042f30c-c922-4835-bf6d-40905f2dc76c. SPL document ID: b4b833f2-4424-46a8-b5df-ad62c36c7d75. Label effective date: July 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tetrabenazine (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: • Depression and Suicidality [see Warnings and Precautions (5.1) ] • Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.4) ] • Akathisia, Restlessness, and Agitation [see Warnings and Precautions (5.5) ] • Parkinsonism [see Warnings and Precautions (5.6) ] • Sedation and Somnolence [see Warnings and Precautions (5.7) ] • QTc Prolongation [see Warnings and Precautions (5.8) ] • Hypotension and Orthostatic Hypotension [see Warnings and Precautions (5.9) ] • Hyperprolactinemia [see Warnings and Precautions (5.10) ] • Binding to Melanin-Containing Tissues [see Warnings and Precautions (5.11) ] Most common adverse reactions (greater than 10% and at least 5% greater than placebo) were: sedation/somnolence, fatigue, insomnia, depression, akathisia, anxiety/anxiety aggravated, nausea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 5042f30c-c922-4835-bf6d-40905f2dc76c. SPL document ID: b4b833f2-4424-46a8-b5df-ad62c36c7d75. Label effective date: July 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tetrabenazine (FDA label)

Tetrabenazine tablets are contraindicated in patients: Who are actively suicidal, or in patients with untreated or inadequately treated depression [see Warnings and Precautions (5.1)] . With hepatic impairment [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)] . Taking monoamine oxidase inhibitors (MAOIs). Tetrabenazine tablets should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Drug Interactions (7.3)] . Taking reserpine. At least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets [see Drug Interactions (7.2)] . Taking deutetrabenazine or valbenazine [see Drug Interactions (7.7)] . • Actively suicidal, or who have depression which is untreated or undertreated (4, 5.1) • Hepatic impairment (4, 8.6, 12.3) • Taking monoamine oxidase inhibitors (MAOIs) or reserpine (4, 7.2, 7.3) • Taking deutetrabenazine or valbenazine (4, 7.7)

Source: FDA prescribing information (DailyMed). Set ID: 5042f30c-c922-4835-bf6d-40905f2dc76c. SPL document ID: b4b833f2-4424-46a8-b5df-ad62c36c7d75. Label effective date: July 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tetrabenazine (FDA label)

Periodically reevaluate the benefit and potential for adverse effects such as worsening mood, cognition, rigidity, and functional capacity. (5.2) Do not exceed 50 mg per day and the maximum single dose should not exceed 25 mg if administered in conjunction with a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine). (5.3, 7.1) Neuroleptic Malignant Syndrome (NMS): Discontinue if this occurs. (5.4, 7.6) Restlessness, agitation, akathisia and parkinsonism: Reduce dose or discontinue if occurs. (5.5, 5.6) Sedation/Somnolence: May impair patient’s ability to drive or operate complex machinery (5.7) QTc prolongation: Not recommended in combination with other drugs that prolong QTc (5.8) 5.1 Depression and Suicidality Patients with Huntington’s disease are at increased risk for depression, suicidal ideation or behaviors (suicidality).

Source: FDA prescribing information (DailyMed). Set ID: 5042f30c-c922-4835-bf6d-40905f2dc76c. SPL document ID: b4b833f2-4424-46a8-b5df-ad62c36c7d75. Label effective date: July 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tetrabenazine (FDA label)

7.1 Strong CYP2D6 Inhibitors In vitro studies indicate that α-HTBZ and β-HTBZ are substrates for CYP2D6. Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) markedly increase exposure to these metabolites. A reduction in tetrabenazine dose may be necessary when adding a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine, quinidine) in patients maintained on a stable dose of tetrabenazine tablets. The daily dose of tetrabenazine tablets should not exceed 50 mg per day and the maximum single dose of tetrabenazine tablets should not exceed 25 mg in patients taking strong CYP2D6 inhibitors [see Dosage and Administration (2.3), Warnings and Precautions (5.3), Use in Specific Populations (8.7), Clinical Pharmacology (12.3)] . 7.2 Reserpine Reserpine binds irreversibly to VMAT2, and the duration of its effect is several days.

Source: FDA prescribing information (DailyMed). Set ID: 5042f30c-c922-4835-bf6d-40905f2dc76c. SPL document ID: b4b833f2-4424-46a8-b5df-ad62c36c7d75. Label effective date: July 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.